Atrial Fibrillation

AI-Guided Cardiac Ablation Outperforms Standard Treatment for Persistent Atrial Fibrillation

2 months ago talkbio0Tagged Artificial Intelligence, Atrial Fibrillation, Cardiac ablation, Electrophysiology (science), Medical service, Pulmonary veins, TAILORED-AF

Volta Medical, artificial intelligence, cardiac ablation, atrial fibrillation, TAILORED-AF trial, pulmonary vein isolation, electrophysiology

Novartis Acquires Anthos Therapeutics for $925M, Regaining Control of Promising Anticoagulant Abelacimab

2 months ago talkbio0Tagged abelacimab, Acquisition, Anthos, Anticoagulants, Atrial Fibrillation, cardiovascular pipeline, Cerebrovascular accident, Factor XI antibody, Novartis

Novartis, Anthos Therapeutics, acquisition, abelacimab, anticoagulant, Factor XI inhibitor, atrial fibrillation, stroke prevention, cardiovascular pipeline

Boston Scientific’s Farapulse PFA System Surpasses $1 Billion in Revenue, Transforming Electrophysiology Market

3 months ago talkbio0Tagged Atrial Fibrillation, Boston Scientific, Electrophysiology (science), Farapulse, field ablation, innovation, Medical Devices, Revenue Milestone

Boston Scientific, Farapulse, pulsed field ablation, atrial fibrillation, electrophysiology, revenue milestone, medical device innovation

Medtronic’s Affera System: A Breakthrough in Electrophysiology with FDA Approval for All-in-One Pulsed Field Ablation

6 months ago talkbio0Tagged Affera, Approved, Atrial Fibrillation, Cardiac ablation, Electrophysiology (science), field ablation, Medtronic, United States Food and Drug Administration

Medtronic, Affera, FDA approval, pulsed field ablation, electrophysiology, atrial fibrillation, cardiac ablation

Bayer’s Asundexian Fails to Prevent Strokes, Jeopardizing $5.5 Billion Blockbuster Hopes

8 months ago talkbio0Tagged Asundexian, Atrial Fibrillation, Bayer, Cerebrovascular accident, Clinical Trials, Factor XI inhibitors

Bayer, asundexian, stroke prevention, atrial fibrillation, Factor XI inhibitors, clinical trials